Bioavailability of once- and twice-daily regimens of didanosine in human immunodeficiency virus-infected children

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 5, 2000, Pages 1375-1376

  Abreu, Thalita ^a   Plaisance, Karen ^b   Rexroad, Vivian ^c   Nogueira, Susie ^a   Oliveira, Ricardo Hugo ^a   Evangelista, Lucia A ^a   Rangel, Rosana ^a   Silva, Irene S ^a   Knupp, Cathy ^d   Lambert, John S ^e  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

^e UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DOSE CALCULATION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; STEADY STATE;

ANTI-HIV AGENTS; BIOLOGICAL AVAILABILITY; CHILD; CHILD, PRESCHOOL; DIDANOSINE; HIV INFECTIONS; HUMANS;

EID: 6744222816     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.5.1375-1376.2000     Document Type: Article

References (11)

1. Balis, F. M., P. A. Pizzo, K. M. Butler, M. E. Hawkins, P. Brouwers, R. N. Husson, F. Jacobsen, S. M. Blaney, J. Gress, P. Jarosinski, and D. G. Poplack. 1992. Clinical pharmacology of 2′,3′-dideoxyinosine in human immunodeficiency virus-infected children. J. Infect. Dis. 165:99-104.
2. Butler, K. M., R. N. Husson, F. M. Balis, P. Brouwers, J. Eddy, D. El-Amin, D. Poplack, S. Santacroce, D. Venzon, L. Wiener, P. Wolters, and P. A. Pizzo. 1991. Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. N. Engl. J. Med. 324:137-144.
3. Drusano, G. L., G. J. Yuen, G. Morse, T. P. Cooley, M. Seidlin, J. S. Lambert, H. A. Liebman, F. T. Valentine, and R. Dolin. 1992. Impact of bioavailability on determination of the maximal tolerated dose of 2′,3′-dideoxyinosine in phase I trials. Antimicrob. Agents Chemother. 36:1280-1283.
4. Gibb, D., M. Barry, S. Ormesher, L. Nokes, M. Seefried, C. Giaquinto, and D. Back. 1995. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection. Br. J. Clin. Pharmacol. 39:527-530.
5. Hoetelmans, R. M., R. P. van Heeswijk, M. Profijt, J. W. Mulder, P. L. Meenhorst, J. M. Lange, P. Reiss, and J. H. Beijnen. 1998. Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV-1 infected individuals. AIDS 12:F211-F216.
6. Keiser, P., D. Turner, O. Ramilo, M. B. Kvanli, J. W. Smith, and N. Nassar. 1998. An open-label pilot study of the efficacy and tolerability of once-daily didanosine versus twice-daily didanosine. Clin. Infect. Dis. 27:400-401.
7. Kline, M. W., C. V. Fletcher, M. E. Federici, A. T. Harris, K. D. Evans, V. L. Rutkiewicz, W. T. Shearer, and L. M. Dunkle. 1996. Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety and immunologic and virologic effects. Pediatrics 97:886-890.
8. Lambert, J. S., M. Seidlin, R. C. Reichman, C. S. Plank, M. Laverty, G. D. Morse, C. Knupp, C. McLaren, C. Pettinelli, F. T. Valentine, and R. Dolin. 1990. 2′,3′-Dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex: a phase I trial. N. Engl. J. Med. 322:1333-1340.
9. Mueller, B. U., P. A. Pizzo, M. Farley, R. N. Husson, J. Goldsmith, A. Kovacs, L. Woods, J. Ono, J. A. Church, P. Brouwers, P. Jarosinski, D. Venzon, and F. M. Balis. 1994. Pharmacokinetic evaluation of the combination of zidovudine and didanosine in children with human immunodeficiency virus infection. J. Pediatr. 125:142-146.
10. Perry, C. M., and J. A. Balfour. 1996. Didanosine: an update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease. Drugs 52:928-962.
11. Reynes, J., R. Denisi, P. Massip, J. Izopel, I. Pellegrin, and M. Segondy. 1999. Once-daily administration of didanosine in combination with stavudine in antiretroviral-naïve patients. The STADI Group. J. Acquir. Immune Defic. Syndr. 22:103-105.